A retrospective study suggested Vistide significantly improved the lives of 70% of severely ill ME/XCFS patients.

A retrospective study suggested Vistide significantly improved the lives of 70% of severely ill ME/XCFS patients.

In a first for ME/CFS, at the HHV6 Conference in Paris Dr. Peterson reported a retrospective study indicated a little used anti-herpesvirus drug called Vistide significantly helped 70% of severely ill patients – with many able to return to work. With this unusually high success rate in this difficult to treat group Peterson called for multi-center studies to build on these results.

Click here to read the blog on the Simmaron Foundation website

Don't Miss Another Blog!

Like this blog? Make sure you don’t miss another by registering for our free ME/CFS and Fibromyalgia blogs here..

×

Take Health Rising's $5 Dollar Challenge! Learn more here

Share This